|
Outlook Therapeutics, Inc. (OTLK) DCF Valuation
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Outlook Therapeutics, Inc. (OTLK) Bundle
Explore Outlook Therapeutics, Inc.'s (OTLK) financial potential with our user-friendly DCF Calculator! Enter your projections for growth, margins, and expenses to calculate the intrinsic value of Outlook Therapeutics, Inc. (OTLK) and refine your investment approach.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITDA | -35.8 | -51.5 | -62.9 | -57.4 | -71,703,235.0 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Depreciation | .6 | .3 | .2 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| EBIT | -36.3 | -51.7 | -63.1 | -57.4 | -71,703,235.0 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Total Cash | 12.5 | 14.5 | 17.4 | 23.4 | 14,927,538.0 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Inventories | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Accounts Payable | 2.4 | 2.2 | 3.5 | 6.6 | 7,968,725.0 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 0 | 0 |
| Tax Rate, % | -0.00371531 | -0.00371531 | -0.00371531 | -0.00371531 | -0.00371531 | -0.00371531 | -0.00371531 | -0.00371531 | -0.00371531 | -0.00371531 |
| EBITAT | -33.2 | -51.7 | -63.1 | -57.4 | -71,705,899.0 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -30.3 | -51.7 | -61.6 | -54.3 | -63,737,180.6 | -7,968,725.0 | .0 | .0 | .0 | .0 |
| WACC, % | 862.85 | 942.89 | 942.89 | 942.89 | 942.89 | 926.88 | 926.88 | 926.88 | 926.88 | 926.88 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -776,013.3 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -776,013 | |||||||||
| Net Debt | -14,629,709 | |||||||||
| Equity Value | 13,853,696 | |||||||||
| Diluted Shares Outstanding, MM | 18,549 | |||||||||
| Equity Value Per Share | 746.88 |
What You Will Receive
- Comprehensive Financial Model: Outlook Therapeutics’ actual data facilitates accurate DCF valuation.
- Complete Forecasting Control: Modify revenue growth, profit margins, WACC, and other essential variables.
- Real-Time Calculations: Automatic updates provide immediate feedback as adjustments are made.
- Professional-Grade Template: A polished Excel file crafted for high-quality valuation presentations.
- Flexible and Reusable: Designed for adaptability, enabling multiple uses for in-depth forecasting.
Key Features
- Comprehensive DCF Calculator: Features detailed unlevered and levered DCF valuation models tailored for Outlook Therapeutics, Inc. (OTLK).
- WACC Calculator: A pre-built Weighted Average Cost of Capital sheet with customizable inputs specific to Outlook Therapeutics, Inc. (OTLK).
- Adjustable Forecast Assumptions: Easily modify growth rates, capital expenditures, and discount rates for Outlook Therapeutics, Inc. (OTLK).
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios for Outlook Therapeutics, Inc. (OTLK).
- Interactive Dashboard and Charts: Visual summaries of key valuation metrics for Outlook Therapeutics, Inc. (OTLK) for straightforward analysis.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Outlook Therapeutics' pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify assumptions.
- Step 5: Evaluate the outputs and utilize the results for investment decisions regarding Outlook Therapeutics, Inc. (OTLK).
Why Choose This Calculator for Outlook Therapeutics, Inc. (OTLK)?
- Accurate Data: Up-to-date financials from Outlook Therapeutics ensure dependable valuation outcomes.
- Customizable: Tailor key inputs like growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: Simple design and clear instructions make it accessible for all users.
Who Should Use This Product?
- Investors: Evaluate Outlook Therapeutics’ valuation before making investment decisions.
- CFOs and Financial Analysts: Optimize valuation assessments and validate financial forecasts.
- Startup Founders: Discover how biotechnology companies like Outlook Therapeutics are valued.
- Consultants: Create comprehensive valuation reports for client presentations.
- Students and Educators: Utilize current data to learn and teach valuation methodologies.
What the Template Contains
- Preloaded OTLK Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.